Fibrosis and portal hypertension are considered risk factors for hepatic resection in cirrhotic patients with hepatocellular carcinoma. Nrf2 is a transcription factor mediated by oxidative stress that regulates the expression of a series of targets with a cytoprotective function and plays a role important in the pathogenesis of liver fibrosis. The present study was set up to investigate the effects of of modulation of the Nrf2/HO-1/CO pathway on liver fibrosis in rats. Liver fibrosis was induced by administration of CCl4 for eight weeks. Thereafter, rats were treated with CORMA1 2mg/kg for two weeks and undergone to partial hepatectomy (lateral left and median lobes, around 70% of liver volume). At 7,15 and 30 days the degree of hepatic regeneration will be analyzed by a volumetric study of the residual liver volume using the Ultrasound Imaging Facility (Fujifilm-Visualsonics Vevo 3100). The results support a role of modulation of the Nrf2/HO-1/CO pathway in the liver regeneration, and simultaneously demonstrate the therapeutic potential of CORMA1 in the treatment of this type of chronic liver disease.
Effects of modulation of the NRF/HO-1/CO pathway in fibrosis and hepatic regeneration / Pesce, A., Mangano, K., Fagone, P., Puleo, S.. - 71:2(2018), pp. 31-61. (14th Congress of the International Society for Experimental Microsurgery Debrecen (Hungary) ).
Effects of modulation of the NRF/HO-1/CO pathway in fibrosis and hepatic regeneration
Pesce A;
2018
Abstract
Fibrosis and portal hypertension are considered risk factors for hepatic resection in cirrhotic patients with hepatocellular carcinoma. Nrf2 is a transcription factor mediated by oxidative stress that regulates the expression of a series of targets with a cytoprotective function and plays a role important in the pathogenesis of liver fibrosis. The present study was set up to investigate the effects of of modulation of the Nrf2/HO-1/CO pathway on liver fibrosis in rats. Liver fibrosis was induced by administration of CCl4 for eight weeks. Thereafter, rats were treated with CORMA1 2mg/kg for two weeks and undergone to partial hepatectomy (lateral left and median lobes, around 70% of liver volume). At 7,15 and 30 days the degree of hepatic regeneration will be analyzed by a volumetric study of the residual liver volume using the Ultrasound Imaging Facility (Fujifilm-Visualsonics Vevo 3100). The results support a role of modulation of the Nrf2/HO-1/CO pathway in the liver regeneration, and simultaneously demonstrate the therapeutic potential of CORMA1 in the treatment of this type of chronic liver disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


